Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
| Price | $1.80 |
|---|---|
| Market cap | $5.51M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | AMEX |
| 52-week range | 1.51-9.59 |
| Beta | 1.48 |
Explore KAPA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.